-

Blackstone Credit & Insurance Leads $7 Billion Investment in Sempra Infrastructure Partners’ Port Arthur LNG Phase 2

NEW YORK--(BUSINESS WIRE)--Blackstone Credit & Insurance (“BXCI”) is leading a $7 billion investment in Sempra Infrastructure Partners’ Port Arthur LNG Phase 2.

Funds managed by BXCI, together with an investor consortium, have acquired a 49.9% minority equity interest in the project. Sempra Infrastructure Partners has retained a 50.1% majority stake.

"We are proud to partner with Sempra Infrastructure on this critical project which will help address rising global energy demands,” said Rick Campbell, Senior Managing Director, Blackstone Credit & Insurance. “The partnership highlights Blackstone’s focus on providing large scale and flexible high-grade capital solutions to the world’s leading corporations.”

“This investment led by Blackstone Credit & Insurance represents an important step forward in the advancement of Port Arthur LNG Phase 2,” said Faisel Khan, Senior Vice President and Chief Financial Officer, Sempra Infrastructure. “We recognize the strength of this distinguished group of investors who share our commitment to delivering reliable energy to global markets. This milestone reflects the strength of our team and our strategy to build world-class infrastructure that supports energy security and economic growth.”

Additional details on Sempra Infrastructure Partners’ Final Investment Decision on Port Arthur LNG Phase 2 and related announcements are available here: https://www.sempra.com/newsroom/press-releases/sempra-announces-strategic-transactions-advancing-goal-building-leading-us.

Morgan Stanley & Co. LLC acted as financial advisor and Milbank LLP acted as legal counsel to BXCI.

About Blackstone Credit & Insurance

Blackstone Credit & Insurance (“BXCI”) is one of the world’s leading credit investors. Our investments span the credit markets, including private investment grade, asset based lending, public investment grade and high yield, sustainable resources, infrastructure debt, collateralized loan obligations, direct lending and opportunistic credit. We seek to generate attractive risk-adjusted returns for institutional and individual investors by offering companies capital needed to strengthen and grow their businesses. BXCI is also a leading provider of investment management services for insurers, helping those companies better deliver for policyholders through our world-class capabilities in investment grade private credit.

Contacts

Thomas Clements
Thomas.clements@blackstone.com
646 482 6088

Blackstone Credit & Insurance

NYSE:BX

Release Versions

Contacts

Thomas Clements
Thomas.clements@blackstone.com
646 482 6088

More News From Blackstone Credit & Insurance

Blackstone Energy Transition Partners Announces Agreement to Acquire Majority Stake in Advanced Cooling Technologies

NEW YORK & LANCASTER, Pa.--(BUSINESS WIRE)--Blackstone (NYSE: BX) and Advanced Cooling Technologies, Inc. (“ACT”) announced today that funds managed by Blackstone Energy Transition Partners (“Blackstone”) have entered into a definitive agreement to acquire a majority stake in ACT, a leading U.S. manufacturer of highly-engineered thermal management and energy efficiency solutions. ACT's executive team will remain in place and continue as significant shareholders in the business. Founded in 2003...

Blackstone Energy Transition Partners Announces Completion of 694MW Magnolia Power Generating Station in Louisiana

NEW YORK & PLAQUEMINE, La.--(BUSINESS WIRE)--Blackstone (NYSE: BX) announced today that private equity funds managed by Blackstone Energy Transition Partners (“Blackstone”) have completed construction of the Magnolia Power Generating Station (“Magnolia Power”), a 694-megawatt greenfield combined cycle gas turbine (“CCGT”) power plant in Plaquemine, Louisiana. Today’s announcement marks the beginning of commercial operations at the plant. Blackstone, through its North American power platform, Ki...

Blackstone Life Sciences Announces a Co-Funding Agreement for Acute Myeloid Leukemia

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blackstone Life Sciences (“BXLS”) today announced a research and development funding agreement to advance the clinical development of bleximenib (JNJ-75276617), an investigational oral menin inhibitor, for acute myeloid leukemia (“AML”). AML is the most common type of acute leukemia in adults, yet continues to be extremely challenging to treat, with the lowest survival of all leukemia types. Johnson & Johnson and funds managed by BXLS will jointly finance...
Back to Newsroom